EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   2.3.2.34 | Atherosclerosis |
34150004 |
Identification of candidate targets for the diagnosis and treatment of atherosclerosis by bioinformatics analysis. |
causal interaction
unassigned |
1
0 |
| 2.3.2.34 | Breast Neoplasms |
32449166 |
UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
3
2
4 |
| 2.3.2.34 | Carcinoma |
17660949 |
Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma. |
unassigned |
0 |
| 2.3.2.34 | Carcinoma |
21477582 |
UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity. |
causal interaction
ongoing research
therapeutic application
unassigned |
4
4
4
0 |
| 2.3.2.34 | Carcinoma |
32651357 |
NEDD8-conjugating enzyme UBC12 as a novel therapeutic target in esophageal squamous cell carcinoma. |
causal interaction
therapeutic application
unassigned |
2
4
0 |
| 2.3.2.34 | Carcinoma |
33945681 |
Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M. |
therapeutic application
unassigned |
1
0 |
| 2.3.2.34 | Carcinoma, Hepatocellular |
32012120 |
UBE2M promotes cell proliferation via the ?-catenin/cyclin D1 signaling in hepatocellular carcinoma. |
causal interaction
diagnostic usage
unassigned |
3
3
0 |
| 2.3.2.34 | Carcinoma, Hepatocellular |
32449166 |
UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
3
2
4 |
| 2.3.2.34 | Carcinoma, Squamous Cell |
33945681 |
Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M. |
therapeutic application
unassigned |
1
0 |
| 2.3.2.34 | Cholangiocarcinoma |
31545502 |
Knockdown of Nedd8?conjugating enzyme UBE2M suppresses the proliferation and induces the apoptosis of intrahepatic cholangiocarcinoma cells. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
4
1 |
